A Double-Blind Comparison of Placebo and WR-122,455 Given as Single Oral Doses to Normal Volunteers,
Abstract
WR-122,455 is a compound having antimalarial activity in animals and of particular interest showing a slow plasma accumulation and clearance after oral administration. This study was designed to determine the safety of WR-122,455 when administered as single oral doses, 5.0 to 240.0 mg, in normal male volunteers. Subjects were followed with daily interviews, periodic physical examinations, measurements of vital signs, tests for photosensitivity, electrocardiograms and laboratory screens. The study demonstrated that single doses of WR-122,455 over the dose ranges studied was safe, although a possibly drug related decrease in hemoglobin and hematocrit occurred at the higher dose levels. A second abnormality of uncertain drug relationship was a rise in SGOT and alkaline phosphatase in one subject. (Author)
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 19, 1971
- Accession Number
- AD0737370
Entities
People
- Anthony B. Czerwinski
- Anthony W. Czerwinski
- Mervin L. Clark
- Thomas L. Whitsett
Organizations
- University of Oklahoma